FDA Reversals in Rare Disease Space Highlight Confusion Around External Controls

Why It Matters

Regulatory uncertainty around external controls can delay or derail costly rare‑disease programs, influencing investment decisions and patient access to breakthrough therapies.

Key Takeaways

• FDA encourages external controls but can demand sham trials
• Companies must engage regulators early for design alignment
• Successful approvals show fit‑for‑purpose external data works
• Reversals highlight risk of relying on real‑world evidence
• Flexibility varies case‑by‑case, increasing scrutiny on bias

Pulse Analysis

The FDA’s 2023‑24 guidance opened the door for rare‑disease developers to lean on historical and real‑world datasets, promising faster timelines and smaller patient cohorts. By allowing external controls in lieu of concurrent placebo arms, the agency aimed to address the ethical and logistical hurdles inherent to ultra‑rare conditions. However, the guidance also warned that data quality, comparability, and pre‑specified statistical plans must be rigorously vetted, setting a high bar for what constitutes a "fit‑for‑purpose" control.

Recent high‑profile reversals illustrate the tension between policy and practice. UniQure’s AMT‑130 gene therapy for Huntington’s disease was initially cleared to use a natural‑history comparator, only to be forced into a sham‑surgery Phase 3 trial months later. Similar push‑backs affected Capricor’s Duchenne cardiomyopathy candidate and Biohaven’s spinocerebellar ataxia drug, where reviewers cited bias and insufficient pre‑specification. Conversely, Denali’s Hunter syndrome therapy and Rezolute’s tumor‑induced hypoglycemia program secured approvals by presenting robust external data that met the agency’s evidentiary standards, underscoring the case‑by‑case nature of FDA scrutiny.

For biotech firms, the lesson is clear: external controls remain a viable pathway, but only when built on transparent, high‑quality datasets and aligned early with regulators. Companies should invest in comprehensive natural‑history registries, engage the FDA during protocol development, and prepare contingency plans for traditional control arms. As the FDA continues to refine its stance, a proactive, data‑driven approach will be the differentiator between accelerated approvals and costly setbacks in the rare‑disease space.